Package Leaflet: Information for the User
NovoEight250UI powder and solvent for solution for injection
NovoEight500UI powder and solvent for solution for injection
NovoEight1000UI powder and solvent for solution for injection
NovoEight1500UI powder and solvent for solution for injection
NovoEight2000UI powder and solvent for solution for injection
NovoEight3000UI powder and solvent for solution for injection
turoctocog alfa (human coagulation factor VIII (rDNA))
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
NovoEight contains the active substance turoctocog alfa, human coagulation factor VIII. Factor VIII is a protein that is naturally found in the blood and helps it to clot.
NovoEight is used to treat and prevent bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) and can be used in all age groups.
In patients with haemophilia A, factor VIII is missing or does not work properly. NovoEight replaces the missing or non-functioning factor VIII and helps the blood to form clots at the site of bleeding.
Do not use NovoEight:
Do not use NovoEight in any of the above cases. If you are not sure, talk to your doctor before using this medicine.
Warnings and precautions
Talk to your doctor before using NovoEight.
There is a small chance that an anaphylactic reaction (a sudden and severe allergic reaction) to NovoEight may occur. The first signs of an allergic reaction are rash, hives, itching, swelling of the lips and tongue, difficulty breathing, wheezing, chest tightness, feeling of general discomfort and dizziness.
If any of these symptoms occur, stop the injection immediately and contact your doctor.
Talk to your doctor if you think that bleeding is not controlled with the dose you are given, as there may be different reasons for this. Some people using this medicine may develop antibodies against factor VIII (also known as factor VIII inhibitors). Factor VIII inhibitors reduce the effectiveness of NovoEight in preventing or controlling bleeding. If this happens, you may need a higher dose of NovoEight or another medicine to control bleeding. Do not increase the total dose of NovoEight to control bleeding without talking to your doctor. You should tell your doctor if you have been previously treated with factor VIII medicines, especially if you have developed inhibitors, as the risk of this happening again is higher.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all factor VIII medicines. These inhibitors, especially in large quantities, prevent the treatment from working properly, so you and your child will be carefully monitored for the development of such inhibitors. If your bleeding or your child's bleeding is not controlled with NovoEight, contact your doctor immediately.
Other medicines and NovoEight
Tell your doctor if you are using, have recently used or might use any other medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Driving and using machines
NovoEight has no influence on the ability to drive and use machines.
NovoEight contains sodium
This medicine contains 30.5 mg of sodium (a major component of table salt/cooking salt) per reconstituted vial. This is equivalent to 1.5% of the maximum recommended daily sodium intake for an adult.
If you are on a low-sodium diet, talk to your doctor.
Treatment with NovoEight should be started by a doctor who has experience in the treatment of patients with haemophilia A. Follow the instructions for administration of this medicine exactly as told by your doctor. If you are not sure, talk to your doctor again.
Your doctor will calculate the dose for you based on your weight and what the medicine is being used for.
Prevention of bleeding
The usual dose of NovoEight is 20 to 50 international units (IU) per kg body weight. The injection is given every 2 or 3 days. In some cases, especially in younger patients, more frequent injections or higher doses may be needed.
Treatment of bleeding
The dose of NovoEight is calculated based on body weight and the desired factor VIII levels. The desired level of factor VIII depends on the severity and location of the bleeding.
Use in children and adolescents
NovoEight can be used in children of all ages. In children (under 12 years) higher doses or more frequent injections may be needed. Adolescents (over 12 years) can use the same dose as adults.
How to administer NovoEight
NovoEight must be injected into a vein. See “Instructions for use of NovoEight” for further information.
If you use more NovoEight than you should
If you use more NovoEight than you should, contact your doctor or go to a hospital immediately.
If you forget to use NovoEight
If you miss a dose and do not know how to make up for it, contact your doctor.
If you stop using NovoEight
If you stop using NovoEight, you will no longer be protected against bleeding or an existing bleed may not stop. Do not stop using NovoEight without talking to your doctor first.
If you have any other questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects can occur with this medicine.
If anaphylactic reactions (severe and sudden allergic reactions) occur (rarely), the injection must be stopped immediately. If you experience any of the following symptoms, contact your doctor immediately:
Severe symptoms, including difficulty swallowing or breathing and redness and swelling of the face or hands, require immediate treatment.
If you experience a severe allergic reaction, your doctor may change your medicine.
In previously untreated children with factor VIII medicines, inhibitor antibodies (see section 2) may be formed very commonly (more than 1 in 10 patients); however, in patients who have received previous treatment with factor VIII (more than 150 days of treatment), the risk is uncommon (less than 1 in 100 patients). If this happens to you or your child, the treatment may stop working properly and you or your child may experience persistent bleeding. If this happens, contact your doctor immediately.
Common side effects (may affect up to 1 in 10 people)
Common side effects (may affect up to 1 in 10 people) in previously untreated patients with factor VIII medicines
Uncommon side effects (may affect up to 1 in 100 people)
Side effects in children and adolescents
The side effects seen in children and adolescents are the same as those seen in adults.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the labels of the vial and the pre-filled syringe after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C to 8°C).
Do not freeze.
Keep the vial in the outer packaging to protect it from light.
Before reconstitution, the NovoEight powder can be stored for:
or
Once the product is removed from the refrigerator, it must not be put back.
Please note the start date and storage temperature on the product packaging.
Once reconstituted, NovoEight must be used immediately. If you cannot use the reconstituted NovoEight solution immediately, you must use it within:
If you are not going to use the reconstituted medicine immediately, store it in the vial. Otherwise, it will no longer be sterile and may cause an infection. Do not store the solution unless you follow the advice of your doctor.
The powder in the vial is a white or slightly yellow powder. If the colour of the powder has changed, do not use it.
The reconstituted solution will be clear to slightly opalescent. Do not use this medicine if you notice it is cloudy or contains visible particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of NovoEight
After reconstitution with the supplied solvent (sodium chloride 9 mg/ml (0.9%) solution for injection), the prepared solution for injection contains 62.5, 125, 250, 375, 500 or 750 IU of turoctocog alfa per ml respectively (based on the turoctocog alfa concentration, i.e., 250, 500, 1000, 1500, 2000 or 3000 IU).
Appearance of the Product and Container Contents
NovoEight is a powder and solvent for solution for injection. Each NovoEight container contains a vial with white or slightly yellowish powder, a pre-filled syringe with 4 ml of a colorless and transparent solution, a plunger rod, and a vial adapter.
Marketing Authorisation Holder and Manufacturer
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
Instructions for Use of NovoEight READ THESE INSTRUCTIONS CAREFULLY BEFORE USING NOVOEIGHT. NovoEight is supplied as a powder. Before injection (administration), it must be reconstituted with the supplied solvent in the syringe. The solvent is a sodium chloride 9 mg/ml (0.9%) solution. Reconstituted NovoEight must be injected into a vein (intravenous injection). The components of this container are designed to reconstitute and inject NovoEight. You will also need an infusion set (tubing and butterfly needle), sterile alcohol swabs, gauze, and bandages. These devices are not included in the NovoEight container. Do not use the equipment without having received proper training from your doctor or nurse. Always wash your hands and ensure the area around you is clean. When preparing and injecting the medicine directly into the veins, it is essential to use a clean and germ-free (aseptic) technique.Improper technique can introduce germs that can infect the blood. Do not open the equipment until you are ready to use it. Do not use the equipment if it has been dropped or damaged.Use a new container instead. Do not use the equipment if it has expired.Use a new container instead. The expiration date is printed on the outer packaging, the vial, the vial adapter, and the pre-filled syringe after EXP. Do not use the equipment if you suspect it is contaminated.Use a new container instead. Do not discard any component until the reconstituted solution has been injected. The equipment is for single use only. | |
Contents The container contains:
| |
| |
| |
If the protective paperis not fully sealed or is broken, do not use the vial adapter. Do not remove the vial adapter from the protective cover with your fingers.If you touch the spike of the vial adapter, you can transfer germs from your fingers. | |
Once attached, do not remove the vial adapter from the vial. | |
Remove the protective coverfrom the vial adapter. Do not remove the vial adapterwhen removing the protective cover. | |
| |
If the syringe cap is loose or missing, do not use the pre-filled syringe. | |
| |
| |
Do not shake the vial, as this will produce foam.
| |
It is recommended to use NovoEight immediately after reconstitution,as, if left, the medicine may no longer be sterile and could cause infections. If you cannot use the reconstituted NovoEight solution immediately,you must use it within 4 hours if stored at room temperature or up to 40°C, or within 24 hours if stored between 2°C and 8°C. Store the reconstituted product in the vial. Do not freeze the reconstituted NovoEight solution or store it in syringes. Do not store the solution without the advice of your doctor. Store the reconstituted NovoEight solution away from direct light. If your dose requires more than one vial, repeat steps Ato Jwith additional vials, vial adapters, and pre-filled syringes until the required dose is reached. | |
If there is too much air in the syringe at any time, inject the air back into the vial.
| |
| |
NovoEight is now ready to be injected into a vein.
Injection of NovoEight through needleless connectors for intravenous catheters (IV) Precaution:the pre-filled syringe is made of glass and is designed to be compatible with standard luer-lock connections. Some needleless connectors with an internal spike are incompatible with the pre-filled syringe. This incompatibility can prevent the administration of the medicine and/or cause damage to the needleless connector. Injection of the solution through a central venous access device (CVAD) such as a central venous catheter or a subcutaneous port:
| |
Disposal
Do not dispose of them as ordinary household waste. | |
Do not disassemble the equipment before disposal. Do not reuse the equipment. |